Latigo Biotherapeutics, Inc. (LTGO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Latigo Biotherapeutics, Inc. (LTGO) closed at USD 15.25 on 2026-10-20, a change of -16.4 % over the past year, with a market capitalization of USD 1.08B.

Latigo Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Latigo Biotherapeutics, Inc. key figures

Previous close

USD 15.25 (2026-10-20)

1-year change

-16.4 %

Market cap

USD 1.08B

Enterprise value

USD 1.35B

P/E ratio (trailing)

-6.48

P/E ratio (forward)

-7.82

EPS (trailing)

-2.52

EPS (forward)

-2.09

PEG ratio

n/a

Price to book

-0.06

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.26

Employees

66

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Latigo Biotherapeutics, Inc. and compare it with other stocks.